Role of Corticosteroids in Palliative Care

REFERENCES

• Doyle D. Oxford textbook of palliative medicine. 3rd ed. Oxford University Press, Oxford; New York 2004
   Google Scholar
• Saag K G. Major Side Effects of Glucocorticoids. 2006, UptoDate: UptoDate
   Google Scholar
• American Pharmaceutical Association. Drug information handbook, pocket. Lexi-Comp Inc. [and the] American Pharmaceutical Associations, Hudson, Ohio
   Google Scholar
• Farr W C. The use of corticosteroids for symptom management in terminally ill patients. Am J Hosp Care Jan-Feb, 1990; 7(1)41–46
   Google Scholar
• Kvale P A, Simoff M, Prakash U B. Lung cancer. Palliative care. Chest. Jan, 2003; 123(1 Suppl)284S–311S
   Google Scholar
• Bilsky M H, Lis E, Raizer J, Lee H, Boland P. The diagnosis and treatment of metastatic spinal tumor. Oncologist. 1999; 4(6)459–469
   PubMedGoogle Scholar
• Barren K D, Hirano A, Araki S, Terry R D. Experiences with metastatic neoplasms involving the spinal cord. Neurology Feb, 1959; 9(2)91–106
   Google Scholar
• Walsh G L, Gokaslan Z L, McCutcheon I E, et al. Anterior approaches to the thoracic spine in patients with cancer: indications and results. Ann Thorac Surg. Dec, 1997; 64(6)1611–1618
   PubMed Web of Science ®Google Scholar
• Siegal T, Siegal T. Current considerations in the management of neoplastic spinal cord compression. Spine. Feb, 1989; 14(2)223–228
   PubMedGoogle Scholar
• Vecht C J, Haaxma-Reiche H, van Putten W L, de Visser M, Vries E P, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology Sep, 1989; 39(9)1255–1257
   Google Scholar
• Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen H H. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A(1)22–27
   PubMed Web of Science ®Google Scholar
• Heimdal K, Hirschberg H, Slettebo H, Watne K, Nome O. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol. Feb, 1992; 12(2)141–144
   Google Scholar
• Taillibert S, Delattre J Y. Palliative care in patients with brain métastases. Curr Opin Oncol. Nov, 2005; 17(6)588–592
   Google Scholar
• Hatam A, Yu Z Y, Bergstrom M, Berggren B M, Greitz T. Effect of dexamethasone treatment on peritumoral brain edema: evaluation by computed tomography. J Comput Assist Tomogr. Jun, 1982; 6(3)586–592
   Google Scholar
• Vecht C J, Hovestadt A, Verbiest H B, van Vliet J J, van Putten W L. Dose-effect relationship of dexa-methasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology Apr, 1994; 44(4)675–680
   PubMedGoogle Scholar
• Hempen C, Weiss E, Hess C F. Dexamethasone treatment in patients with brain métastases and primary brain tumors: do the benefits outweigh the side-effects?. Support Care Cancer May, 2002; 10(4)322–328
   Google Scholar
• Gerrard G E, Franks K N. Overview of the diagnosis and management of brain, spine, and meningeal métastases. J Neurol Neurosurg Psychiatry Jun, 2004; 75(Suppl 2)37–42
   Google Scholar
• Cairncross J G, Kim J H, Posner I B. Radiation therapy for brain métastases. Ann Neurol. Jun, 1980; 7(6)529–541
   Google Scholar
• Schiff D, Batchelor T, Wen P Y. Neurologic emergencies in cancer patients. Neurol Clin. May, 1998; 16(2)449–483
   Google Scholar
• Feuer D J, Broadley K E. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000, 2: CD001219
   Google Scholar
• Ripamonti C, Fagnoni E, Magni A. Management of symptoms due to inoperable bowel obstruction. Tumori May-Jun, 2005; 91(3)233–236
   Google Scholar
• Hardy J, Ling J, Mansi J, et al. Pitfalls in pla-cebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. Palliât Med. Nov, 1998; 12(6)437–442
   Google Scholar
• Laval G, Girardier J, Lassauniere J M, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?. Palliât Med. Jan, 2000; 14(1)3–10
   Google Scholar
• Fainsinger R L, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage. Jan, 1994; 9(1)12–18
   Google Scholar
• Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. Apr 1, 2001; 19(7)2091–2097
   Google Scholar
• Sigsgaard T, Herrstedt J, Andersen L J, et al. Granisetron compared with prednisolone plus meto-pimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer May, 1999; 80(3–4)412–418
   Google Scholar
• Sigsgaard T, Herrstedt J, Christensen P, Andersen O, Dombernowsky P. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer May, 2000; 8(3)233–237
   Google Scholar
• Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. N Engl J Med. Jan 5, 1995; 332(1)1–5
   PubMed Web of Science ®Google Scholar
• Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med. May 25, 2000; 342(21)1554–1559
   PubMed Web of Science ®Google Scholar
• Popiela T, Lucchi R, Giongo F. Methyl-prednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Pre-terminal Cancer Study Group. Eur J Cancer Clin Oncol. Dec, 1989; 25(12)1823–1829
   PubMedGoogle Scholar
• Inoue A, Yamada Y, Matsumura Y, et al. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer Aug, 2003; 11(8)528–532
   PubMed Web of Science ®Google Scholar
• Greenberg D B, Sawicka J, Eisenthal S, Ross D. Fatigue syndrome due to localized radiation. J Pain Symptom Manage Jan, 1992; 7(1)38–45
   Google Scholar
• Irvine D, Vincent L, Graydon J E, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs. Oct, 1994; 17(5)367–378
   PubMedGoogle Scholar
• Bukberg J, Penman D, Holland J C. Depression in hospitalized cancer patients. Psychosom Med. May-Jun 1984; 46(3)199–212
   Google Scholar
• Rao A, Cohen H J. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004, 32: 150–157
   Google Scholar
• Fleishman S B. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr. 2004, 32: 119–123
   Google Scholar
• Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep Jul-Aug, 1985; 69(7–8)751–754
   PubMedGoogle Scholar
• Rousseau P. The palliative use of high-dose corticosteroids in three terminally ill patients with pain. Am J Hosp Palliât Care Sep-Oct, 2001; 18(5)343–346
   Google Scholar
• Delia Cuna G R, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. Dec, 1989; 25(12)1817–1821
   Google Scholar
• Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. C A Cancer J Clin. Mar-Apr, 2002; 52(2)72–91
   Google Scholar
• Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. Nov 8, 1997; 315(7117)1219–1222
   Web of Science ®Google Scholar
• Morley J E, Thomas D R, Wilson M M. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. Apr, 2006; 83(4)735–743
   PubMed Web of Science ®Google Scholar
• Willox J C, Corr J, Shaw K, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed). 1984, 288: 27
   Google Scholar
• Moertel C G, Schutt A J, Reitemeier R J, Hahn R G. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer Jun, 1974; 33(6)1607–1609
   PubMed Web of Science ®Google Scholar
• Loprinzi C L, Kugler J W, Sloan J A, et al. Randomized comparison of megestrol acetate versus dexa-methasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. Oct, 1999; 17(10)3299–3306
   PubMed Web of Science ®Google Scholar
• Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. J Pain SymptomManage. Sep, 2002; 24(3)328–334
   PubMedGoogle Scholar
• Nauck F, Ostgathe C, Klaschik E, et al. Drugs in palliative care: results from a representative survey in Germany. Palliât Med. Mar, 2004; 18(2)100–107
   PubMed Web of Science ®Google Scholar